Skip to content
WeighLab
Menu

Evidence

Evidence-based research

Every claim on WeighLab is tied to primary research or official labeling. Every claim on GLP-1 cost and efficacy, tied to primary research or official labeling each row below shows how many primary sources the piece cites, so you can see what is behind a conclusion before you open it.

54 explainers · 195 primary sources cited

Looking for a specific company rather than the science? All 529 providers we have modeled are in the provider review index, and the ranked shortlists are on the rankings page.

Filter by topic

54 explainers across 11 topics

What a GLP-1 actually costs

Cash prices, the gap between a sticker and a year, and what the first month hides.

Compounded vs brand-name

The price difference, the legal framework behind it, and what the FDA does and does not verify.

How a GLP-1 actually works — and what doesn't

The real mechanism behind the drug class, what's actually in the pen, and an honest look at the patches, pills and supplements marketed as a substitute.

Choosing the provider and the dose

Vetting an operator and following the labeled schedule once you've picked a molecule.

Comparing the GLP-1 drugs and brands

Same drug class, different molecules, doses and brand names — where the real differences, and the real prices, actually are.

Side effects, safety and stopping

What the pivotal trials and dedicated safety reviews actually report — GI effects, body composition, and what happens when treatment ends.

Interactions, life stage and organ-specific risk

What the label and the literature say about drinking, other medications, pregnancy and fertility, hair, skin, and the pancreas and gallbladder — beyond the standard GI-effects list.

Using a GLP-1 day to day

The practical mechanics after the prescription — how to inject, what the evidence says about doses below the labeled schedule, and what to do at a plateau.

New molecules, new indications, and what's next

Drugs and uses moving through the pipeline right now — an FDA-approved second indication, an oral small-molecule contender, an investigational triple agonist, and emerging trial evidence outside weight loss.

Provider bench tests

One company at a time: the rung you can actually buy for a month, the rung the marketing would rather you filed, and every place a provider's own pages disagree with each other.